08:25 AM EDT, 08/19/2024 (MT Newswires) -- Monte Rosa Therapeutics ( GLUE ) said Monday it has dosed the first participants in a phase 1 trial evaluating MRT-6160, its experimental molecular glue degrader targeting VAV1 for autoimmune diseases.

Initial results are due in Q1 2025, the company said.

Monte Rosa said the study will assess the safety, pharmacokinetics, and target degradation of MRT-6160, intended to potentially treat autoimmune and inflammatory conditions by degrading proteins difficult to target with conventional drugs.

Preclinical results have indicated "encouraging results" for MRT-6160 in models of rheumatoid arthritis and other autoimmune disorders, the company said.

The company plans to use the phase 1 data to advance proof-of-concept studies in conditions like ulcerative colitis and rheumatoid arthritis, according to Chief Executive Markus Warmuth.